AstraZeneca has reported positive “high-level” outcomes from the Phase III MATTERHORN trial of Imfinzi (durvalumab) with FLOT chemotherapy.

Merck’s lupus drug enpatoran has failed to meet the primary endpoint in a subgroup of patients, but the drug's development is ...

Persica's antibiotic-based drug could benefit patients with chronic lower back pain who are suffering from an infection in ...

The US FDA has ordered BioNTech to immediately halt its Phase I/II trial of BNT165e, a malaria vaccine candidate, pending ...

Amgen and AstraZeneca have reported outcomes from the WAYPOINT trial of Tezspire for treating chronic rhinosinusitis with ...

NeOnc claims that its novel intranasal delivery platform will be able to bypass the blood-brain barrier and better target ...

The Phase I trial will recruit approximately 98 healthy volunteers and adults living with atopic dermatitis at a single site ...

Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial.

Trevi Therapeutics has finished enrolling subjects in a trial of investigational Haduvio for treating chronic cough in IPF ...

The gene therapy has shown promise in a Phase I/II clinical trial. Image credit: Shutterstock / Anamaria Mejia. Elixirgen ...

The Phase III trial met the primary and secondary endpoints of reducing tics in children and adult patients with Tourette syndrome.

Overall survival data was not yet mature with less than a quarter of the required number of events having occurred. Credit: Shutterstock / Maria Sbytova. Pharma giant Pfizer and Arvinas’s human ...